-+ 0.00%
-+ 0.00%
-+ 0.00%

Nasus Pharma names Brendan P. O’Grady CEO, replacing Dan Teleman

PUBT·07/28/2026 11:43:45
Listen to the news
Nasus Pharma names Brendan P. O’Grady CEO, replacing Dan Teleman
  • Nasus Pharma named Brendan P. O’Grady chief executive officer, effective July 27, 2026, replacing Dan Teleman.
  • O’Grady previously spent 21 years at Teva, including CEO of Teva USA, later served as CEO of Assertio Holdings.
  • Initial priorities include commercial planning for NS002, pipeline advancement, business development, supported by the Nasax intranasal platform.
  • NS002 is slated to enter a pivotal trial in Q4 2026, with topline data expected in Q1 2027.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Nasus Pharma Ltd. published the original content used to generate this news brief on July 28, 2026, and is solely responsible for the information contained therein.